Key facts
- It has raised $43.5M; the latest was Later Stage VC in Nov 2024.
- Notable investors include Nippon Venture Capital, Resona Capital, FFG Venture Business Partners, Hiroshima Venture Capital, Innovation Engine — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Two Cells
- ·The full record, as it builds
Funding rounds
No funding rounds for Two Cells are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Two Cells
Developer of regenerative medicine intended to regenerate tissues and organs that cannot be regenerated naturally. The company's medicine uses mesenchymal stem cells which is a treatment method in which MSC is taken out, increased in number outside the body and transplanted into the patient's body, enabling patients to select new treatment methods through the spread of regenerative medicine.
- Sector
- Healthcare
- HQ
- Hiroshima, Japan
- Founded
- 2003
- Website
- twocells.com/
- Ownership
- Privately Held (backing)
Two Cells doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Two Cells shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Two Cells in its N-PORT filings yet. We sweep new filings monthly.